Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eleanor Malone

Editor-in-Chief, Commercial Insights

London, UK

Eleanor directs editorial content produced by the Commercial Pharma Insights team (Scrip, Generics Bulletin and In Vivo) in the US and Europe, liaising closely with counterparts in policy and regulatory coverage and in Asia. She oversees and contributes to daily analytical content based on biopharma industry developments and trends, interviewing key experts and industry leaders. Eleanor joined Citeline predecessor Informa in 2000 as companies reporter on Scrip, and has held a number of editorial roles on Pharma Intelligence's pharma and medtech publications. She has interviewed countless industry leaders and specialists, explored business developments and strategy, pipeline trends, policy and regulatory stories, delved into M&A, licensing, partnerships, financing, financial reports, clinical trial updates, market trends and more. She regularly appears on conference panels and in the media to discuss matters relating to the biopharma industry. She has an MA in modern languages from the University of Edinburgh and previously worked as a translator of European business news for the Financial Times.

Latest From Eleanor Malone

Titans Of Pharma: J&J Back On Top For CEO Remuneration

J&J topped the league table for CEO pay in 2023, a position it has held for three of the four past years. Meanwhile, the two companies that arguably generated the most buzz in 2023 neatly depict the stark contrast between the US and Europe when it comes to executive remuneration.

Sales & Earnings Business Strategies

Top 10 Drugs Q1 2024: Keytruda Reigns, Trikafta Debuts

Keytruda enjoyed its fifth consecutive quarter as the world’s top-selling drug in the first three months of 2024. As Comirnaty and Spikevax fell out of the list, Vertex’s cystic fibrosis pill Trikafta/Kaftrio became one of the top 10 best-selling drugs for the first time.

Sales & Earnings Commercial

Titans Of Pharma: J&J Back On Top For CEO Remuneration

J&J topped the league table for CEO pay in 2023, a position it has held for three of the four past years. Meanwhile, the two companies that arguably generated the most buzz in 2023 neatly depict the stark contrast between the US and Europe when it comes to executive remuneration.

Leadership Companies

Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff

Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.

Market Intelligence Sales & Earnings

Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff

Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.

Sales & Earnings Evaluate Data

20 Voices: What Does 2024 Hold For Biopharma?

20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.

Artificial Intelligence Business Strategies
See All
UsernamePublicRestriction

Register